{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-23-000020","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.995276+00:00","generated_at":"2026-06-18T00:11:45.621033+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Halozyme says EPO revokes Janssen co-formulation patent; reaffirms 2023 guidance","bullets":["EPO Opposition Division revoked Janssen's European Patent EP3370770B1 for DARZALEX SC co-formulation.","Halozyme reiterates 2023 revenue guidance of $815M-$845M and royalty revenue of $445M-$455M.","Affirms total royalty revenue projection of ~$1B by 2027 and thereafter to at least 2030.","License with Janssen: co-formulation patents do not extend royalty step-down beyond 2024 in EU, 2027 in US.","Written decision expected in months; if appeal filed, patent remains in force until final decision."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-23-000020","json":"https://secwatch.observer/filing/0001159036-23-000020.json","markdown":"https://secwatch.observer/filing/0001159036-23-000020.md","text":"https://secwatch.observer/filing/0001159036-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000020/0001159036-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000020/halo-20230315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:11:45.621033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}